RxDoctor Payments Data

Ryan Su

Family · Savannah, GANPI 1487383675

Payments from drug & device makers

$8,994in general payments, 2019–2025

Across 512 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$813
  • Lilly USA, LLC$740
  • Pfizer$545
  • Otsuka America Pharmaceutical, Inc.$522
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$494
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$8,994100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,994 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$24,821
Medicare patients
150
Services billed
602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide132$139,129
OzempicSemaglutide111$138,499
JardianceEmpagliflozin25$34,316
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$28,324
EliquisApixaban23$25,720
FarxigaDapagliflozin Propanediol16$22,825
TrulicityDulaglutide13$17,717
WegovySemaglutide13$17,085
GemtesaVibegron17$13,593
TradjentaLinagliptin16$13,192
Tresiba Flextouch U-200Insulin Degludec15$9,661
Repatha SureclickEvolocumab12$8,845
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,080
MyrbetriqMirabegron12$6,052
Albuterol Sulfate HfaAlbuterol Sulfate61$1,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$740$156,846145 claims
Novo NordiskOzempic, Wegovy$813$155,584124 claims
Boehringer IngelheimJardiance, Tradjenta$166$47,50841 claims
AstraZenecaFarxiga, Breztri Aerosphere$344$30,90527 claims
GSKTrelegy Ellipta$253$28,32429 claims
PfizerEliquis$545$25,72023 claims
Sumitomo Pharma America, Inc.Gemtesa$95$13,59317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →